Press Releases: Crucell

June 10, 2011

Biological Mimetics, Inc. Announces Vaccine Research Agreement With Crucell Holland BV

Collaboration to Focus on Biological Mimetics’ Proprietary Immune Refocusing Technology

Frederick, MD – Biological Mimetics, Inc. (“BMI”), the developer of Immune Refocusing Technology, today announced a collaborative research relationship with Crucell Holland BV (Crucell), a subsidiary of Crucell NV. The joint effort will focus on the application of BMI’s Immune Refocusing Technology (“IRT”) to the development of human influenza vaccines. Additional details of the collaboration were not disclosed.

We are extremely pleased to be working with Crucell,” said Dr. Peter L. Nara, CEO of BMI. “This research program presents another opportunity for BMI to demonstrate the utility of Immune Refocusing Technology to the design of next generation prophylactic vaccines in human influenza.”

Morgan Joseph TriArtisan LLC acted as exclusive financial advisor to Biological Mimetics, Inc. with respect to the transaction.

About BMI - Biological Mimetics, Inc. (“BMI”) was formed to commercialize innovative pharmaceutical products that improve the quality of life and overall state of public health by combating resistant and emerging diseases in human and veterinary medicine. As a result of BMI’s elucidation of “Deceptive Imprinting,” a mechanism of antigenic variation and immunodominance used by microbial pathogens and cancer cells to evade the host immune system, BMI developed “Immune Refocusing Technology” (“IRT”) to circumvent such evasion mechanisms. Through the application of IRT, BMI strives to: (1) generate vaccines against pathogens for which no effective vaccine exists and
(2) improve upon current commercially available vaccines that exhibit strain-limited or serotype-limited protection. IRT is able to alter the natural antigenicity and immunogenicity of targeted protein antigens making it a valuable tool to induce and select rare and more effective therapeutic and diagnostic monoclonal antibodies. IRT can also be
utilized to immune dampen therapeutic proteins and biologics to improve biological halflife and safety profiles for other biologics including cancer vaccines.

BMI was founded in 1996 by scientists from the National Cancer Institute. The Company’s headquarters and R&D facilities are located in Frederick, Maryland. The Crucell collaboration is the second research collaboration BMI has entered within the past year. In December 2010, BMI announced its collaboration with GlaxoSmithKline in the
application of IRT to the development of human vaccines.